Pharmacology Examination Topics 1 semester

1. Pharmacodynamic principles. Receptors and subtypes

General description of parasympathetic nervous system from pharmacological point of view (neurotransmitters and receptors)

Antihypertensive mode of action of thiazide diuretics and the side effects, osmotic diuretics

2. Dose-response relationships. Efficacy and potency

Directly acting parasympathomimetics

Calcium channel blockers

3. Graded and quantal dose-response relationships. Therapeutic index, therapeutic window

Parasympatholytics

Centrally acting sympathoplegic drugs

4. Agonists and antagonists. Antagonism on the receptor level

Sympathomimetics

Pharmacology of renin/angiotensin system

5. Antagonism. Non-receptorial antagonism

Non-selective α -adrenoceptor blockers

General description of antiarrhythmic drugs. Vaughan Williams classification

6. Control of receptor expression. Receptor diseases and receptors and disease

β-adrenoceptor blockers

Treatment of myocardial ischemia especially the treatment of angina pectoris

7. Desensitization, tachyphylaxys and tolerance

Indirectly acting parasympathomimetics

Drugs used in the treatment of hyperlipidemias

8. The movement of drugs through biological membranes

Structure-activity relationships demonstrated among sympathomimetics

Drugs used for the treatment of congestive heart failure

9. Distribution of drugs in the body: the apparent volume of distribution (V)

General description of sympathetic nervous system from pharmacological point of view (neurotransmitters and receptors)

Characterization of quinidine, lidocaine, and amiodarone

10. Elimination of drugs: the half-life (T_{1.2})

Pharmacological tools to influence the sympathetic neurotransmission

Expectorants and antitussives

11. The clearance

Selective α-adrenoceptor blockers

Pharmacology of the liver and the gall bladder

12. Plasma concentrations after repeated administration: loading dose and

maintenance dose

Metabolism of chatecholamines and pharmacological modulation

Pharmacological treatment of bronchial asthma

13. Absorption of drugs and ion trap

Comparison of elimination of acetylcholine (Ach) and norepinephrine/noradrenaline from the synaptic cleft and the possibilities of pharmacological modulation

Therapeutic importance of diuretics, mode of action and classification. Antialdosterone compounds and other potassium-sparing diuretics

14. Bioavailability. AUC

Compare the effects of norepinephrine/noradrenaline, epinephrine/adrenaline and isoprenaline

Inhibitors of carboanhydrase enzyme, thiazides and other sulfonamide type diuretics, high-ceiling diuretics (loop diuretics) and antidiuretics

15. First pass effect

Synthesis, storage, release and elimination of acetylcholine (Ach). Demonstration of Dale's experiment

Agents used in anemias

16. Drug elimination: I. Biotransformation

Non-adrenergic, non-cholinergic (NANC) transmission

Drugs used in coagulation disorders

17. Factors influencing the drug elimination

Uptake mechanisms, substrates and inhibitors

Drugs used in acid-peptic disease

18. Drug elimination: II. Excretion

α2 sympathomimetics and the concept of "false transmitter"

Laxatives, antidiarrheal drugs. Drugs in the treatment of chronic inflammatory bowel disease, antiobesity drugs

19. Factors influencing the drug effect. Preclinical phase of drug development

Pharmacology of cardiac glycosides

Drugs promoting gastrointestinal motility. Emetics and antiemetic drugs

20. Drug interactions. Biologicals (biological therapy), special considerations with respect to their development.

Positive inotropic substances except cardiac glycosides

Pharmacotherapeutic approach to exocrine pancreatic diseases

21. Clinical phase of drug development.

Adrenergic neuron blockers and reserpine. Antihypertensive mode of action of β -blockers Botanical/herbal remedies